Mounjaro for Weight Loss: Evidence, Eligibility, Coverage

Mounjaro is not FDA approved for weight loss. It is approved for type 2 diabetes and heart risk. Zepbound, with the same ingredient, is approved for weight loss. In SURMOUNT-1, people on Zepbound lost 20.9% of body weight on average, vs 3.1% on placebo.

For weight loss: Not an approved use
Active ingredient: tirzepatide
How it is taken: weekly injection
Best result (SURMOUNT-1): 20.9% weight loss

Mounjaro overview

How long it remains in your body

Its half-life is about 5 days: after 5 d, half is gone, and about 3% remains after five half-lives (25 d).

Weight loss in the main trial

In SURPASS-1, people with type 2 diabetes lost 7.8 kg over 40 weeks, compared with 1 kg on placebo.

The Price as time goes by

Monthly prices in US dollars cover the list price and self-pay offers, with each figure taken from the maker's price page.

Sources: FDA label (DailyMed), healthsystemtracker.org, pricinginfo.lilly.com.

Who qualifies for it?

Mounjaro: who qualifies
Who sets the rule	Who qualifies for it?
FDA label	Used with diet and exercise, it lowers blood sugar in adults and children 10 and older who have type 2 diabetes.
FDA label	It reduces the risk of a heart attack, stroke, or heart-related death in adults with type 2 diabetes at high risk.
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	first, a diet and activity program lasting 6 months

These sources are listed: DailyMed FDA label, aetna.com

Weight loss study results

Mounjaro was not studied in its own trial for this group. The listed studies involve other brands that use the same ingredient as Mounjaro.

Trials for tirzepatide, the same ingredient
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SURMOUNT-1	Zepbound	Adults with obesity or overweight, without diabetes	72 weeks	2,539	20.9% weight loss	3.1% on placebo
SURMOUNT-5	Zepbound	Adults with obesity, without type 2 diabetes	72 weeks	751	20.2% weight loss	Not listed

Trial sources: SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-5 (PubMed)

What is different for weight loss?

Mounjaro: what the label says about weight loss
What changes	What the label says
Acute Pancreatitis	Can cause inflammation of the pancreas. If stomach pain is severe, persists, and sometimes reaches your back, stop taking the medicine and get care.
Acute Gallbladder Disease	Gallstones and gallbladder inflammation can happen. If you have a fever, yellow skin or eyes, or upper right belly pain, report it.

Source: FDA label on DailyMed.

Label warnings: FDA label on DailyMed

Coverage for weight loss

Medicare Part D offers no coverage for a GLP-1 used only for weight loss.

Medicaid coverage that includes weight-loss GLP-1s normally requires prior authorization.

Sources: humana.com, KFF

Used for weight loss

GLP-1 medicines and weight loss
Medicine	For weight loss	How it is taken	Trial result
Wegovy	FDA approved	weekly injection or daily tablet	14.9% weight loss
Zepbound	FDA approved	weekly injection	20.9% weight loss
Foundayo	FDA approved	daily tablet	11.1% weight loss
Saxenda	FDA approved	daily injection	7.4% weight loss
Mounjaro	Not an approved use	weekly injection	Not listed
Ozempic	Not an approved use	weekly injection	Not listed
Rybelsus	Not an approved use	daily tablet	Not listed
Trulicity	Not an approved use	weekly injection	Not listed
Victoza	Not an approved use	daily injection	Not listed
Byetta	Not an approved use	twice-daily injection	Not listed